Month: February 2021

AMSTERDAM and NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) — TomTom (TOM2), the location technology specialist, and Precisely, the global leader in data integrity, today announced an extension of their long-standing relationship. TomTom will provide Precisely with its leading map and traffic datasets, helping Precisely customers leverage important context to make better-informed, more confident business decisions.Precisely will use TomTom’s highly accurate map information as well as its historic and real-time traffic data – sourced from over 600 million connected devices. This map and traffic data can help financial services organizations reduce fraud, enable insurance companies to better manage location risk, and improve targeted retail marketing campaigns by providing better customer insights.“Fresh, comprehensive maps and real-time,...

(Figures in brackets refer to the corresponding period of 2019)Recent highlights Successfully maintained its order backlog through Covid-19, although utilization in 2020  was significantly impactedOperating status and financial resultsUtilisation of 25% in Q4 (23%)Despite lower average day rates, reported EBITDA of USD 0.7 million (USD 6.4 million negative) due to good cost performance; while the underlying EBITDA adjusted for one-offs was USD 2.8 million (USD 0.4 million negative)Cash flow from operations was USD 2.3 million negative (USD 9.5 million positive)Commercial statusSecured a 90-day contract with an option of up to 60 days for ConocoPhillips commencing Q2 2022Secured an extension for the Safe Notos with Petrobras in Brazil through to mid-November 2021, with a 30-day SPS time-out in Q1 2021Awarded a 117-day contract in Trinidad...

VÉLIZY-VILLACOUBLAY, France — February 4, 2021 — Dassault Systèmes (Euronext Paris: #13065, DSY.PA) announces IFRS unaudited financial results for the fourth quarter and year ended December 31, 2020. The Group’s Board of Directors reviewed these results on February 3, 2021. This press release also includes financial information on a non-IFRS basis and reconciliations with IFRS figures in the Appendix to this communication. Highlights(Unaudited, all revenue growth in constant currencies)Q4 benefited from large deal activity on both a license and subscription basisFY IFRS EPS of €1.86 and non-IFRS EPS of €3.77FY Recurring Revenue up 27% to €3.2 billion, 80% of total software (IFRS and non-IFRS)Cash flow from operations up 5% to €1.24 billion for 2020Strong MEDIDATA performance: revenues, customer growth, and backlog for 2021DS initiates 2021...

VÉLIZY-VILLACOUBLAY, France — 4 février 2021 — Dassault Systèmes (Euronext Paris : #13065, DSY.PA), publie ses résultats financiers non audités en normes IFRS pour le 4ème trimestre et l’exercice clos le 31 décembre 2020. Ces résultats ont été revus par le Conseil d’administration le 3 février 2021. Ce communiqué comporte également une information financière exprimée en normes non-IFRS, pour laquelle un tableau de réconciliation avec les données IFRS figure en annexe.Faits marquants(données non auditées et croissance du chiffre d’affaires à taux de change constants)Dynamisme des grands contrats, licences et souscription, au 4ème trimestreBNPA IFRS 2020 de 1,86 euro et BNPA non-IFRS de 3,77 eurosCroissance de 27% du chiffre d’affaires récurrent à 3,2 milliards d’euros en 2020, représentant 80% du chiffre d’affaires logiciel (IFRS et non-IFRS)Progression...

New agreement builds on previous success in speeding study start-up and completionNew York, New York – February 4, 2021 – Medidata, a Dassault Systèmes company and the global leader in creating end-to-end solutions to support the entire clinical development process, today announced its expanded partnership with Horizon Therapeutics plc (NASDAQ: HZNP). Starting in 2017 with one technology solution, Medidata will now provide a diverse suite of solutions for Horizon’s clinical research needs in multiple therapeutic areas including ophthalmology, rheumatology, and nephrology.“We’re delighted to be a key partner to Horizon and its exceptional journey that benefits patients by advancing science and treatments,” said Tarek Sherif, co-founder and co-CEO, Medidata. “Medidata’s goal is to facilitate Horizon’s path forward using advanced analytics...

Ce nouvel accord s’appuie sur les succès enregistrés précédemment afin d’accélérer le lancement et la réalisation d’études cliniquesVÉLIZY-VILLACOUBLAY (Yvelines) et NEW YORK (État de New York), le 4 février 2021 — Medidata, une société du groupe de Dassault Systèmes, leader mondial des solutions de bout en bout au service de l’ensemble du processus des essais cliniques, annonce l’élargissement de son partenariat avec Horizon Therapeutics plc (NASDAQ : HZNP). Après avoir entamé cette collaboration en 2017 avec la fourniture d’une unique solution technologique, Medidata propose une suite complète de solutions qui répondent aux besoins de recherche clinique d’Horizon dans de multiples domaines thérapeutiques, parmi lesquels l’ophtalmologie, la rhumatologie et la néphrologie.« Nous nous réjouissons d’être un partenaire clé d’Horizon et de...

Steve Muehler, the Founder & Senior Managing Member of Private Placement Markets today announced the firm is expanding its new Insurance Brokerage, which is set to begin offering Commercial Insurance Products starting this month, by including Life Insurance and Annuities starting in the Spring of 2021. According to Steve Muehler, “given our vast relationships with many Life Insurance Companies through out the United States through our Commercial Real Estate Financing operations, it only made sense to include Life Insurance and Annuities with out forthcoming Commercial Insurance Products and Services.” Steve Muehler went on to state that, “our research of the market shows that roughly 1 in 5 individuals believe they are under insured with their current life insurance policies. Of that number, more than half visited life insurance company...

REDWOOD CITY, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD) today announced the pricing of its underwritten public offering of 5,797,101 shares of common stock at a public offering price of $45.00 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by Revolution Medicines. In addition, Revolution Medicines has granted the underwriters a 30-day option to purchase up to an additional 869,565 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Revolution Medicines, are expected to be approximately $260.9 million, excluding any exercise of the underwriters’ option...

DUBLIN, Ireland and CHICAGO, Feb. 03, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 34,782,609 ordinary shares (or pre-funded warrants in lieu thereof) at a public offering price of $1.15 per share, less underwriting discounts and commissions. In addition, the Company has granted the underwriter an option for a period of 30 days to purchase up to an additional 5,217,391 ordinary shares on the same terms and conditions. All of the shares (or...